BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korean Liver Cancer Study Group (KLCSG);  National Cancer Center; Korea (NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver. 2015;9:267-317. [PMID: 25918260 DOI: 10.5009/gnl14460] [Cited by in Crossref: 25] [Cited by in F6Publishing: 90] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Park JH, Kim DH, Kim SH, Kim MY, Baik SK, Hong IS. The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity. World J Surg 2018;42:1514-22. [PMID: 29026966 DOI: 10.1007/s00268-017-4275-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kim CY, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5844. [PMID: 28079817 DOI: 10.1097/MD.0000000000005844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
3 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
4 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer 2017;17:279. [PMID: 28420329 DOI: 10.1186/s12885-017-3267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
6 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Rich NE, Parikh ND, Singal AG. Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. Semin Liver Dis 2017;37:296-304. [PMID: 29272892 DOI: 10.1055/s-0037-1608775] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
9 Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU; Korean TACE Study Group. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Med J 2021;62:12-20. [PMID: 33381930 DOI: 10.3349/ymj.2021.62.1.12] [Reference Citation Analysis]
10 Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Dig Dis Sci. 2017;62:3235-3242. [PMID: 28983724 DOI: 10.1007/s10620-017-4775-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
11 Xu W, Rao Q, An Y, Li M, Xu G, Sang X, Lu X, Zhang Z, Mao Y. Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: A double-center study from China. Medicine (Baltimore). 2018;97:e11800. [PMID: 30095644 DOI: 10.1097/md.0000000000011800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
13 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
14 Kim DH, Kim B, Youn SY, Kim H, Choi JI. Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1763. [PMID: 34679461 DOI: 10.3390/diagnostics11101763] [Reference Citation Analysis]
15 Min JH, Kim YK, Sinn DH, Choi SY, Jeong WK, Lee WJ, Ha SY, Ahn S, Kim MJ. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdom Radiol (NY) 2018;43:2309-20. [PMID: 29470629 DOI: 10.1007/s00261-018-1480-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kumar G, Goldberg SN, Gourevitch S, Levchenko T, Torchilin V, Galun E, Ahmed M. Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation. Radiology 2018;286:524-36. [PMID: 28880787 DOI: 10.1148/radiol.2017162943] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
18 Wang XD, Peng JB, Zhou CY, Que Q, Li HY, He Y, Yang H. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles. Oncol Rep 2020;43:1915-27. [PMID: 32186781 DOI: 10.3892/or.2020.7545] [Reference Citation Analysis]
19 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
20 Lee H, Yoon JH, Kim H, Yi NJ, Hong SK, Yoon KC, Kim HS, Ahn SW, Choi JY, Choi Y, Lee HW, Yi JY, Lee KB, Lee KW, Suh KS. False Positive Diagnosis of Hepatocellular Carcinoma in Liver Resection Patients. J Korean Med Sci. 2017;32:315-320. [PMID: 28049244 DOI: 10.3346/jkms.2017.32.2.315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
21 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Kim JS, Lee JK, Baek SY, Yun HI. Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdom Radiol 2020;45:211-9. [DOI: 10.1007/s00261-019-02277-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One 2019;14:e0216173. [PMID: 31048923 DOI: 10.1371/journal.pone.0216173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
24 Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Semin Intervent Radiol 2020;37:456-65. [PMID: 33328701 DOI: 10.1055/s-0040-1719186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, Han KH, Kim DY. A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. Clin Mol Hepatol 2020;26:24-32. [PMID: 31104456 DOI: 10.3350/cmh.2018.0065] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
26 Zhang TQ, Huang ZM, Shen JX, Chen GQ, Shen LJ, Ai F, Gu YK, Yao W, Zhang YY, Guo RP, Chen MS, Huang JH. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. Therap Adv Gastroenterol 2019;12:1756284819862966. [PMID: 31489030 DOI: 10.1177/1756284819862966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
29 Shim CW, Park JW, Kim SH, Kim JS, Kim BH, Hong EK. Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area. Therap Adv Gastroenterol. 2017;10:529-536. [PMID: 28804513 DOI: 10.1177/1756283x17710247] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
30 Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol 2017;23:42-50. [PMID: 28263954 DOI: 10.3350/cmh.2016.0058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
31 Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016;5:97-106. [PMID: 27386428 DOI: 10.1159/000367759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
32 Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730. [PMID: 30640924 DOI: 10.1371/journal.pone.0210730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
33 Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer 2020;20:937. [PMID: 32993594 DOI: 10.1186/s12885-020-07105-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
35 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. Korean J Intern Med 2020;35:65-78. [PMID: 31189301 DOI: 10.3904/kjim.2018.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
36 Lee K, Lee KB, Yi NJ, Suh KS, Jang JJ. Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy. J Pathol Transl Med 2017;51:79-86. [PMID: 28013531 DOI: 10.4132/jptm.2016.10.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
37 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
38 Lee W, Han HS, Ahn S, Yoon YS, Cho JY, Choi Y. Correlation between Resection Margin and Disease Recurrence with a Restricted Cubic Spline Model in Patients with Resected Hepatocellular Carcinoma. Dig Surg 2018;35:520-31. [PMID: 29342456 DOI: 10.1159/000485805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
39 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
40 Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K, Swamidas J, Shetty N, Patkar S, Patil P, Ostwal V, Mehta S, Goel M. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol 2019;92:20181053. [PMID: 31219706 DOI: 10.1259/bjr.20181053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
41 Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol 2019;25:223-33. [PMID: 30661336 DOI: 10.3350/cmh.2018.0107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
42 Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Reference Citation Analysis]
43 Kim JH, Sinn DH, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Dig Dis Sci 2016;61:3354-62. [PMID: 27435325 DOI: 10.1007/s10620-016-4255-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
44 Kim JK, Kim JW, Lee IJ, Joo SM, Lee KH, Cho ES, Yu JS, Jeon TJ, Kim Y, Lee JI, Lee KS. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. Radiat Oncol 2017;12:133. [PMID: 28810886 DOI: 10.1186/s13014-017-0873-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Seo YS, Kim MS, Kang JK, Jang WI, Kim HJ, Cho CK, Yoo HJ, Paik EK, Cha YJ, Yoon JS. The Clinical Utilization of Radiation Therapy in Korea between 2011 and 2015. Cancer Res Treat 2018;50:345-55. [PMID: 28449574 DOI: 10.4143/crt.2017.096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
46 Song KD, Rhim H, Lee MW, Kang TW, Lim S. A radiofrequency device for tract ablation after liver biopsy: a single-institution human feasibility study. Br J Radiol 2018;91:20170585. [PMID: 29356562 DOI: 10.1259/bjr.20170585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Joo YY, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression. Sci Rep 2019;9:9137. [PMID: 31235729 DOI: 10.1038/s41598-019-45537-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
48 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
49 Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget. 2016;7:40756-40766. [PMID: 27213593 DOI: 10.18632/oncotarget.9450] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
50 Kim JH, Sinn DH, Gwak GY, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim KY, Kim K, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: A retrospective cohort study. Medicine (Baltimore) 2016;95:e4735. [PMID: 27583916 DOI: 10.1097/MD.0000000000004735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci. 2018;63:1062-1071. [PMID: 29442276 DOI: 10.1007/s10620-018-4934-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
52 Ju YC, Jun DW, Choi J, Saeed WK, Lee HY, Oh HW. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World J Gastroenterol 2018; 24(40): 4606-4614 [PMID: 30386110 DOI: 10.3748/wjg.v24.i40.4606] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
53 Nam JY, Sinn DH, Bae J, Jang ES, Kim JW, Jeong SH. Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. JHEP Rep 2020;2:100175. [PMID: 33117971 DOI: 10.1016/j.jhepr.2020.100175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Igaki H, Mizumoto M, Okumura T, Hasegawa K, Kokudo N, Sakurai H. A systematic review of publications on charged particle therapy for hepatocellular carcinoma. Int J Clin Oncol 2018;23:423-33. [PMID: 28871342 DOI: 10.1007/s10147-017-1190-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
55 Kim YA, Kang D, Moon H, Sinn D, Kang M, Woo SM, Chang YJ, Park B, Kong SY, Guallar E, Shin SY, Gwak G, Back JH, Lee ES, Cho J. Survival in untreated hepatocellular carcinoma: A national cohort study. PLoS One 2021;16:e0246143. [PMID: 33539397 DOI: 10.1371/journal.pone.0246143] [Reference Citation Analysis]
56 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
57 Kim W, Jeong D, Chung J, Lee D, Joo S, Jang ES, Choi YJ, Yoon H, Shin CM, Park YS, Jeong SH, Kim N, Lee DH, Kim JW. Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. Sci Rep 2019;9:3236. [PMID: 30824851 DOI: 10.1038/s41598-019-39573-9] [Reference Citation Analysis]
58 Kim JY, Sinn DH, Gwak GY, Choi GS, Saleh AM, Joh JW, Cho SK, Shin SW, Carriere KC, Ahn JH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clin Mol Hepatol 2016;22:250-8. [PMID: 27377909 DOI: 10.3350/cmh.2016.0015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
59 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
60 Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, Hyun D, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res 2020;99:238-46. [PMID: 33029483 DOI: 10.4174/astr.2020.99.4.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Tian H, Cao S, Hu M, Wang Y, Fu Q, Pan Y, Qin T. Identification of predictive factors in hepatocellular carcinoma outcome: A longitudinal study. Oncol Lett 2020;20:765-73. [PMID: 32566003 DOI: 10.3892/ol.2020.11581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Purcell Y, Copin P, Paradis V, Vilgrain V, Ronot M. Lessons learnt from pathologic imaging correlation in the liver: an historical perspective. Br J Radiol 2019;92:20180701. [PMID: 30604641 DOI: 10.1259/bjr.20180701] [Reference Citation Analysis]
63 Nam JY, Choe AR, Sinn DH, Lee JH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Lee JM, Chung JW, Choi SY, Lee JK, Baek SY, Lee HA, Kim TH, Yoo K. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:504. [PMID: 32487089 DOI: 10.1186/s12885-020-06975-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
64 Choi GH, Jang ES, Kim JW, Jeong SH. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol 2021; 27(27): 4453-4467 [PMID: 34366616 DOI: 10.3748/wjg.v27.i27.4453] [Reference Citation Analysis]
65 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
66 Zeng ZC, Seong J, Yoon SM, Cheng JC, Lam KO, Lee AS, Law A, Zhang JY, Hu Y. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer. 2017;6:264-274. [PMID: 29234630 DOI: 10.1159/000475768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
67 Cha H, Park HC, Yu JI, Kim TH, Nam TK, Yoon SM, Yoon WS, Kim JW, Kim MS, Jang HS, Choi Y, Kim JH, Kay CS, Jung I, Seong J. Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). Cancer Res Treat. 2017;49:61-69. [PMID: 27338036 DOI: 10.4143/crt.2016.097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
68 Lee MW, Lim HK. Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. World J Gastroenterol 2018; 24(46): 5215-5222 [PMID: 30581270 DOI: 10.3748/wjg.v24.i46.5215] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
69 Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-51. [PMID: 32492765 DOI: 10.3350/cmh.2020.0004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
70 Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. Curr Oncol 2021;28:965-77. [PMID: 33617513 DOI: 10.3390/curroncol28010095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Park SH, Kim JC, Kang MK. Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol 2016; 22(32): 7311-7321 [PMID: 27621577 DOI: 10.3748/wjg.v22.i32.7311] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
72 Choi SH, Seong J. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. Clin Mol Hepatol. 2018; Epub ahead of print. [PMID: 29439305 DOI: 10.3350/cmh.2017.0073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
73 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Kim BH, Park JW, Kim JS, Lee SK, Hong EK. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma. Gut Liver. 2019;13:342-348. [PMID: 30600675 DOI: 10.5009/gnl18345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
75 Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, Huo YR, Santhakumar C, Lee AU, Yang J. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp 2019;3:49. [PMID: 31853685 DOI: 10.1186/s41747-019-0126-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
76 Goh MJ, Oh JH, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer 2021;10:52-62. [PMID: 33708639 DOI: 10.1159/000512239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
77 Park Y, Lee JH, Sinn DH, Park JY, Kim MA, Kim YJ, Yoon JH, Kim DY, Ahn SH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clin Transl Gastroenterol 2021;12:e00290. [PMID: 33433118 DOI: 10.14309/ctg.0000000000000290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Bae SH, Kim MS, Jang WI, Kay CS, Kim W, Kim ES, Kim JH, Kim JH, Yang KM, Lee KC. Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group. Jpn J Clin Oncol. 2016;46:363-369. [PMID: 26826720 DOI: 10.1093/jjco/hyv209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
79 Park JH, Choi J, Jun DW, Han SW, Yeo YH, Nguyen MH. Low Alanine Aminotransferase Cut-Off for Predicting Liver Outcomes; A Nationwide Population-Based Longitudinal Cohort Study. J Clin Med 2019;8:E1445. [PMID: 31514449 DOI: 10.3390/jcm8091445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
80 Yu JI, Park HC, Jung SH, Choi C, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Sahinbas H, Paik SW. Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial.Oncotarget. 2017;8:52651-52664. [PMID: 28881759 DOI: 10.18632/oncotarget.17072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
81 Kang SH, Cho H, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yi NJ, Lee KW, Suh KS, Yoon JH. Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. J Korean Med Sci 2018;33:e283. [PMID: 30402048 DOI: 10.3346/jkms.2018.33.e283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
82 Hong SK, Lee KW, Hong SY, Suh S, Hong K, Han ES, Lee JM, Choi Y, Yi NJ, Suh KS. Efficacy of Liver Resection for Single Large Hepatocellular Carcinoma in Child-Pugh A Cirrhosis: Analysis of a Nationwide Cancer Registry Database. Front Oncol 2021;11:674603. [PMID: 33996606 DOI: 10.3389/fonc.2021.674603] [Reference Citation Analysis]
83 Kim T, Woo S, Han S, Suh CH, Lee DH, Lee JM. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol 2020;30:1624-33. [DOI: 10.1007/s00330-019-06499-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Ryu MR, Kang ES, Park HD. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. J Clin Lab Anal 2019;33:e22921. [PMID: 31131509 DOI: 10.1002/jcla.22921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
85 Bae SH, Park HC. Local modalities for inoperable hepatocellular carcinoma: radiofrequency ablation versus stereotactic body radiotherapy. Ann Transl Med 2018;6:S3. [PMID: 30613579 DOI: 10.21037/atm.2018.08.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
86 Labgaa I, Taffé P, Martin D, Clerc D, Schwartz M, Kokudo N, Denys A, Halkic N, Demartines N, Melloul E. Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:138-47. [PMID: 32399428 DOI: 10.1159/000505093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Chen YX, Zhuang Y, Yang P, Fan J, Zhou J, Hu Y, Zhu WC, Sun J, Zeng ZC. Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:1533033820937002. [PMID: 32613904 DOI: 10.1177/1533033820937002] [Reference Citation Analysis]
89 Moon H, Choi JE, Lee IJ, Kim TH, Kim SH, Ko YH, Kim HB, Nam BH, Park JW. All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. J Cancer Res Clin Oncol 2017;143:2327-39. [PMID: 28744575 DOI: 10.1007/s00432-017-2480-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
90 Kim JM, Cho SY, Rhu J, Jung M, Her JH, Lim O, Choi GS, Shin EC, Hwang YK, Joh JW. Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study. Ann Hepatobiliary Pancreat Surg 2021;25:206-14. [PMID: 34053923 DOI: 10.14701/ahbps.2021.25.2.206] [Reference Citation Analysis]
91 Kim YI, Kim HS, Park JW. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. PLoS One. 2016;11:e0157299. [PMID: 27304617 DOI: 10.1371/journal.pone.0157299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
92 Kim M, Kang TW, Cha DI, Jang KM, Kim YK, Kim SH, Sinn DH, Kim K. Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. Korean J Radiol 2019;20:236-45. [PMID: 30672163 DOI: 10.3348/kjr.2018.0339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]